Matches in Wikidata for { <http://www.wikidata.org/entity/Q60228496> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- Q60228496 description "artículu científicu espublizáu n'agostu de 2009" @default.
- Q60228496 description "im August 2009 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60228496 description "scientific article published on 01 August 2009" @default.
- Q60228496 description "wetenschappelijk artikel" @default.
- Q60228496 description "наукова стаття, опублікована в серпні 2009" @default.
- Q60228496 name "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 name "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 type Item @default.
- Q60228496 label "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 label "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 prefLabel "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 prefLabel "Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b" @default.
- Q60228496 P1433 Q60228496-D7A361C4-A72A-491B-8856-11D322829553 @default.
- Q60228496 P1476 Q60228496-74429C3A-CD12-4713-9F3C-FB6D8AD64412 @default.
- Q60228496 P2093 Q60228496-04688AE2-1126-4DD7-BD23-EBCF602F8A4E @default.
- Q60228496 P2093 Q60228496-11315B50-C9DB-4B1F-912D-F2C0DDA0DDF1 @default.
- Q60228496 P2093 Q60228496-28A8095C-1E50-489F-B315-75A589817669 @default.
- Q60228496 P2093 Q60228496-3DC145FF-DFDF-4729-B2BD-A8E9A10FDB40 @default.
- Q60228496 P2093 Q60228496-48CF0A6D-7202-43DF-836A-35894EBC8F1F @default.
- Q60228496 P2093 Q60228496-5654BDFE-9217-4987-BE31-9F97022371FA @default.
- Q60228496 P2093 Q60228496-6650C83F-6FE6-41F0-8D07-A7586E8DA4B8 @default.
- Q60228496 P2093 Q60228496-7A4B7079-4697-4E08-99DA-AEF4E7C4B3B7 @default.
- Q60228496 P2093 Q60228496-9016A407-1D05-414B-898C-F7374AC61CCC @default.
- Q60228496 P2093 Q60228496-A5EF6DB7-E684-415C-AB0C-AB4E136C9130 @default.
- Q60228496 P2093 Q60228496-D5439DFC-968B-41D6-9614-236B6DAA5249 @default.
- Q60228496 P2093 Q60228496-F2C599E0-C6B5-4ECD-9479-4DF3DA8BE01E @default.
- Q60228496 P2093 Q60228496-F4E4AFAD-06D4-4007-8505-89F607B9A3A5 @default.
- Q60228496 P304 Q60228496-4F3E0A97-FFB1-45F1-8783-7E3E4B3B7EFF @default.
- Q60228496 P31 Q60228496-3511043C-9377-45DA-B197-83AE4175C717 @default.
- Q60228496 P356 Q60228496-2421877A-DB40-45EE-B65B-712818962ED4 @default.
- Q60228496 P433 Q60228496-F4AE96A4-6A6F-4C34-BDF5-DFC3843DC20C @default.
- Q60228496 P478 Q60228496-4EAE1B6B-5DC9-4C04-8FFB-2CD876DB5AF3 @default.
- Q60228496 P50 Q60228496-37A9C94F-4E49-4519-8696-52118D9DE950 @default.
- Q60228496 P50 Q60228496-BEF7B1A8-F040-4AC8-940A-5140210D2FBF @default.
- Q60228496 P577 Q60228496-DE3D1137-2111-493B-AC11-9DD457939B2A @default.
- Q60228496 P6179 Q60228496-F1CE0F72-2114-44BC-9766-DBC5643FE801 @default.
- Q60228496 P698 Q60228496-B33F90E5-0F82-4E1C-8A00-552E174A618E @default.
- Q60228496 P921 Q60228496-410515A4-E59B-4898-A71F-EEA1327B1EE3 @default.
- Q60228496 P921 Q60228496-E5E15E14-0201-4175-B20E-2126844439BB @default.
- Q60228496 P356 ART.24638 @default.
- Q60228496 P698 19644849 @default.
- Q60228496 P1433 Q23929027 @default.
- Q60228496 P1476 "Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis" @default.
- Q60228496 P2093 "Bernardo Antonio Pons-Estel" @default.
- Q60228496 P2093 "Elizabeth C Hsia" @default.
- Q60228496 P2093 "Eric Jason B Amante" @default.
- Q60228496 P2093 "Ingrid Strusberg" @default.
- Q60228496 P2093 "Larry W Moreland" @default.
- Q60228496 P2093 "Mahboob U Rahman" @default.
- Q60228496 P2093 "Melvin Churchill" @default.
- Q60228496 P2093 "Mittie K Doyle" @default.
- Q60228496 P2093 "Patrick Durez" @default.
- Q60228496 P2093 "Roy M Fleischmann" @default.
- Q60228496 P2093 "Sudha Visvanathan" @default.
- Q60228496 P2093 "Weichun Xu" @default.
- Q60228496 P2093 "Won Park" @default.
- Q60228496 P304 "2272-2283" @default.
- Q60228496 P31 Q13442814 @default.
- Q60228496 P356 "10.1002/ART.24638" @default.
- Q60228496 P433 "8" @default.
- Q60228496 P478 "60" @default.
- Q60228496 P50 Q19859634 @default.
- Q60228496 P50 Q63367206 @default.
- Q60228496 P577 "2009-08-01T00:00:00Z" @default.
- Q60228496 P6179 "1025511601" @default.
- Q60228496 P698 "19644849" @default.
- Q60228496 P921 Q187255 @default.
- Q60228496 P921 Q422248 @default.